Table 2.

Overall survival in the COMFORT trials.

Median Follow-up	HR (95% CI)	p Value*
COMFORT-I	RUX (n = 155) vs PBO (n = 154)
1 year (51 weeks) [33]	0.50 (0.25–0.98)	0.04
2 years (102 weeks) [58]	0.58 (0.36–0.95)	0.03
3 years (149 weeks) [52]	0.69 (0.46–1.03)	0.067
COMFORT-II	RUX (n = 146) vs BAT (n = 73)
1 year (52 weeks) [34]	0.70 (0.20–2.49)
2 years (112 weeks) [62]	0.51 (0.27–0.99)	0.041
3 years (151 weeks) [53]	0.48 (0.28–0.85)	0.009
COMFORT-I + COMFORT-II	RUX (n = 301) vs PBO or BAT (n = 227)
3 years [63]	0.65 (0.46–0.90)	0.01

^*p values not adjusted for multiple comparisons.

BAT: Best available therapy; HR: Hazard ratio; PBO: Placebo; RUX: Ruxolitinib.